Get the Stockscreener App
3.02
0.33%
0.01
Relmada Therapeutics Inc stock is traded at $3.02, with a volume of 153.77K.
It is up +0.33% in the last 24 hours and down -16.34% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$3.01
Open:
$3.02
24h Volume:
153.77K
Relative Volume:
0.88
Market Cap:
$95.80M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.7056
EPS:
-4.28
Net Cash Flow:
$-51.66M
1W Performance:
-7.08%
1M Performance:
-16.34%
6M Performance:
-9.58%
1Y Performance:
+7.86%
1-Day Range:
$2.9761
$3.22
1-Week Range:
$2.96
$3.425
52-Week Range:
$1.88
$7.2225
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RLMD | 3.03 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 22.16 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.141 | 297.56M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.16 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.61 | 114.98M | 0 | 0 | 0 | 0.00 |
| JUNE | 4.95 | 63.87M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Relmada Therapeutics initiates Phase 1 dosing with REL-P11 - TipRanks
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease - The Manila Times
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Relmada Therapeutics reports Q3 financials, focuses on REL-1017 - Investing.com Nigeria
Relmada Therapeutics hopes to hit big milestones by year-end - Green Market Report
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights - GuruFocus.com
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance UK
Relmada Therapeutics Inc. Reports Q3 2024 Financial Results - TipRanks
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - Quantisnow
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
Relmada Therapeutics (RLMD) Set to Announce Earnings on Thursday - MarketBeat
3 US Penny Stocks To Monitor In October 2024 - Simply Wall St
Q3 Earnings Estimate for RLMD Issued By Leerink Partnrs - MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Purchased by Renaissance Technologies LLC - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Shares Down 0.3%Should You Sell? - MarketBeat
Roblox Corp general counsel sells $774,810 in stock By Investing.com - Investing.com Canada
Roblox Corporation [RBLX] moved down -1.09: Why It’s Important - The DBT News
RBLX (Roblox Corporation) may reap gains as insiders became active recently - Knox Daily
Hancock Whitney Corp Reduces Stake in Relx Plc (NYSE:RELX) - Defense World
Bet on a Slow March Higher in Roblox (NYSE:RBLX) Stock with a Credit Spread - Nasdaq
RELX rises Monday, outperforms market - MarketWatch
Relx Plc (NYSE:RELX) Shares Bought by Mercer Global Advisors Inc. ADV - Defense World
Financial Health Report: Relmada Therapeutics Inc (RLMD)’s Ratios Tell a Tale - The Dwinnex
What's Going On With Richtech Robotics Stock? - Benzinga
Relx (NYSE:RELX) Hits New 12-Month High at $48.32 - MarketBeat
A new trading data show Relmada Therapeutics Inc (RLMD) is showing positive returns. - SETE News
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - Defense World
Understanding the Risks of Investing in Relmada Therapeutics Inc (RLMD) - Knox Daily
Why ResMed Stock Tumbled by 5% Today - The Motley Fool
Monitoring Collegium Pharmaceutical Inc (COLL) after recent insider movements - Knox Daily
Is Marvell Technology, Inc. (MRVL) The Worst 5G Stock to Buy According to Short Sellers? - Yahoo Finance
Relmada Therapeutics (NASDAQ:RLMD) Raised to Buy at Jefferies Financial Group - MarketBeat
Relmada Therapeutics Inc Inc. (RLMD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Relmada stock jumps as Jefferies upgrades (NASDAQ:RLMD) - Seeking Alpha
Relmada stock's "risk/reward setup" could lead to big upsideJefferies - Investing.com
Finansavisen - Finansavisen
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - PR Newswire
Relmada Therapeutics Inc (RLMD) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Insider Spends US$395k Buying More Shares In Relmada Therapeutics - Yahoo Finance
Relmada Therapeutics CFO buys $149,700 in company stock - Investing.com India
Analyst sustains stock target, outperform on Relmada amid insider buys - Investing.com India
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) - Yahoo Finance
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Th - GuruFocus.com
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) By GuruFocus - Investing.com Canada
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140 - GuruFocus.com
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares By GuruFocus - Investing.com Canada
Relmada Therapeutics director buys $33,280 in company stock - Investing.com India
Relmada therapeutics CEO acquires shares worth over $395k - Investing.com India
Relmada Therapeutics director buys $33,280 in company stock By Investing.com - Investing.com Canada
Insider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Buys 8,194 Shares of Stock - MarketBeat
Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares - Yahoo Finance
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
| CASAMENTO CHARLES J | Director |
Sep 09 '24 |
Buy |
2.56 |
13,000 |
33,280 |
13,000 |
| Shenouda Maged | Chief Financial Officer |
Sep 11 '24 |
Buy |
2.95 |
24,120 |
71,154 |
88,335 |
| Shenouda Maged | Chief Financial Officer |
Sep 10 '24 |
Buy |
2.73 |
21,118 |
57,652 |
64,215 |
| Shenouda Maged | Chief Financial Officer |
Sep 09 '24 |
Buy |
2.55 |
8,194 |
20,895 |
43,097 |
| Kelly Paul Edward | Director |
Sep 09 '24 |
Buy |
2.59 |
25,000 |
64,750 |
212,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Jan 30 '24 |
Buy |
3.90 |
40,999 |
159,949 |
216,564 |
| TRAVERSA SERGIO | Chief Executive Officer |
Jan 29 '24 |
Buy |
3.71 |
31,541 |
117,036 |
175,565 |
| TRAVERSA SERGIO | Chief Executive Officer |
Jan 31 '24 |
Buy |
4.00 |
27,460 |
109,752 |
244,024 |
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):